Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Halozyme Therapeutics stock on March 9th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Halozyme Therapeutics Trading Up 1.4%

NASDAQ:HALO traded up $0.89 during mid-day trading on Thursday, hitting $66.32. 124,124 shares of the company’s stock were exchanged, compared to its average volume of 1,828,724. The company has a 50 day simple moving average of $69.52 and a 200-day simple moving average of $69.07. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $82.22. The firm has a market capitalization of $7.86 billion, a P/E ratio of 26.63, a PEG ratio of 0.26 and a beta of 1.03.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same quarter in the prior year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of recent analyst reports. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Finally, Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $78.56.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $48,754,030. The trade was a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at $477,200.20. This trade represents a 55.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 118,857 shares of company stock valued at $8,279,587 in the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently modified their holdings of the stock. Hsbc Holdings PLC increased its stake in shares of Halozyme Therapeutics by 1,202.4% in the 4th quarter. Hsbc Holdings PLC now owns 82,323 shares of the biopharmaceutical company’s stock valued at $5,584,000 after acquiring an additional 76,002 shares in the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of Halozyme Therapeutics by 20.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 5,586 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 946 shares in the last quarter. World Investment Advisors bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $674,000. Corient Private Wealth LLC increased its stake in shares of Halozyme Therapeutics by 1,554.7% in the 4th quarter. Corient Private Wealth LLC now owns 196,600 shares of the biopharmaceutical company’s stock valued at $13,231,000 after acquiring an additional 184,719 shares in the last quarter. Finally, MidFirst Bank bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $210,000. Institutional investors own 97.79% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.